Actively Recruiting
Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-12-19
300
Participants Needed
3
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to examine the exposure to atmospheric pollutants in a group of non-smoking patients suffering from lung cancer, chronic obstructive pulmonary disease (COPD), and leukemia. The exposure to atmospheric pollutants will be assessed simultaneously in a group of healthy volunteers. The ultimate goal of the study is to enhance the understanding of the mechanisms by which atmospheric pollutants act, in order to develop new tools that can help halt or at least delay the development of diseases associated with pollution.
CONDITIONS
Official Title
Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Non-smokers, defined as having smoked less than 100 cigarettes in lifetime and not currently smoking
- Patients diagnosed with COPD of any severity (FEV1/FVC < 0.7 after bronchodilation) or lung neoplasm of any type and stage, or leukemia of any type
- Healthy volunteers without COPD, solid tumors, or leukemia, working at participating medical centers
- Signed informed consent
You will not qualify if you...
- Alpha-1 antitrypsin deficiency for COPD patients
- Workers from the Department of Pneumology and Respiratory Intensive Care, IRCCS AOU of Bologna, S. Orsola Polyclinic (for healthy volunteers)
- Previous or current diagnosis of solid tumors, myelodysplastic syndromes, or myeloproliferative neoplasms for oncology patients
- Previous or current treatment with antineoplastic agents for oncology patients
- Workers from the Department of Medical Oncology, IRCCS AOU of Bologna, S. Orsola Polyclinic (for healthy volunteers)
- Previous diagnosis of solid tumors, myelodysplastic syndromes, or myeloproliferative neoplasms for hematology patients
- Previous treatment with antineoplastic agents such as alkylating agents, hydroxyurea, topoisomerase II inhibitors, or lenalidomide for hematology patients
- Genetic conditions like Fanconi anemia, ataxia-telangiectasia, Down syndrome, xeroderma pigmentosum, or Li-Fraumeni syndrome for hematology patients
- Infection with HIV, human T-lymphotropic virus types 1 or 2, or Epstein-Barr virus for hematology patients
- Workers from the Hematology Department, Policlinico Riuniti di Foggia (for healthy volunteers)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
2
Respiratory and Critical Care Unit, IRCCS Azienda Ospedaliera-Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
3
Ematology Unit, Azienda Ospedaliero-Universitaria, Policlinico Riuniti di Foggia
Foggia, Foggia, Italy, 71122
Actively Recruiting
Research Team
S
Stefano Nava, MD
CONTACT
F
Francesco Saverio Violante, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here